Aerovate Therapeutics (AVTE) Competitors $2.53 0.00 (0.00%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$2.53 +0.00 (+0.16%) As of 03/28/2025 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVTE vs. GOSS, CMPS, SEPN, CADL, DSGN, AVIR, ZYBT, CRVS, MBX, and IMMPShould you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include Gossamer Bio (GOSS), COMPASS Pathways (CMPS), Septerna (SEPN), Candel Therapeutics (CADL), Design Therapeutics (DSGN), Atea Pharmaceuticals (AVIR), Zhengye Biotechnology (ZYBT), Corvus Pharmaceuticals (CRVS), MBX Biosciences (MBX), and Immutep (IMMP). These companies are all part of the "pharmaceutical products" industry. Aerovate Therapeutics vs. Gossamer Bio COMPASS Pathways Septerna Candel Therapeutics Design Therapeutics Atea Pharmaceuticals Zhengye Biotechnology Corvus Pharmaceuticals MBX Biosciences Immutep Gossamer Bio (NASDAQ:GOSS) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, profitability, institutional ownership, valuation, risk, dividends and media sentiment. Do insiders & institutionals have more ownership in GOSS or AVTE? 81.2% of Gossamer Bio shares are owned by institutional investors. 5.0% of Gossamer Bio shares are owned by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts rate GOSS or AVTE? Gossamer Bio presently has a consensus target price of $7.75, suggesting a potential upside of 562.39%. Aerovate Therapeutics has a consensus target price of $2.25, suggesting a potential downside of 11.07%. Given Gossamer Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Gossamer Bio is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Aerovate Therapeutics 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community believe in GOSS or AVTE? Gossamer Bio received 135 more outperform votes than Aerovate Therapeutics when rated by MarketBeat users. Likewise, 66.67% of users gave Gossamer Bio an outperform vote while only 54.29% of users gave Aerovate Therapeutics an outperform vote. CompanyUnderperformOutperformGossamer BioOutperform Votes15466.67% Underperform Votes7733.33% Aerovate TherapeuticsOutperform Votes1954.29% Underperform Votes1645.71% Which has more risk and volatility, GOSS or AVTE? Gossamer Bio has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Which has better earnings and valuation, GOSS or AVTE? Aerovate Therapeutics has lower revenue, but higher earnings than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGossamer Bio$114.70M2.32-$179.82M-$0.26-4.50Aerovate TherapeuticsN/AN/A-$75.52M-$2.99-0.85 Does the media favor GOSS or AVTE? In the previous week, Gossamer Bio had 7 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 9 mentions for Gossamer Bio and 2 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 1.06 beat Gossamer Bio's score of 0.85 indicating that Aerovate Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Gossamer Bio Positive Aerovate Therapeutics Positive Is GOSS or AVTE more profitable? Aerovate Therapeutics' return on equity of -90.19% beat Gossamer Bio's return on equity.Company Net Margins Return on Equity Return on Assets Gossamer BioN/A -127.28% -22.12% Aerovate Therapeutics N/A -90.19%-77.47% SummaryGossamer Bio beats Aerovate Therapeutics on 11 of the 16 factors compared between the two stocks. Remove Ads Get Aerovate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTE vs. The Competition Export to ExcelMetricAerovate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$73.05M$6.90B$5.63B$7.84BDividend YieldN/A2.74%4.59%4.01%P/E Ratio-0.857.1723.3718.70Price / SalesN/A218.12387.8490.67Price / CashN/A65.6738.1734.64Price / Book0.646.396.894.23Net Income-$75.52M$142.12M$3.20B$247.15M7 Day Performance0.40%-5.06%-2.99%-2.18%1 Month Performance4.12%-7.49%1.63%-5.68%1 Year Performance-91.44%-10.91%9.45%-0.74% Aerovate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTEAerovate Therapeutics0.7401 of 5 stars$2.53flat$2.25-11.1%-91.4%$73.05MN/A-0.8520Earnings ReportNews CoveragePositive NewsGOSSGossamer Bio3.7963 of 5 stars$1.28-7.9%$9.20+618.8%-0.8%$290.84M$114.70M-4.00180Analyst RevisionCMPSCOMPASS Pathways3.6563 of 5 stars$3.11+0.3%$21.83+602.0%-64.7%$288.21MN/A-1.41120Analyst ForecastSEPNSepterna2.1209 of 5 stars$6.37+7.6%$34.00+433.8%N/A$282.85M$981,000.000.00N/AEarnings ReportUpcoming EarningsAnalyst ForecastNews CoverageGap DownCADLCandel Therapeutics2.661 of 5 stars$8.66+7.4%$21.00+142.5%+276.6%$281.24M$120,000.00-5.0160DSGNDesign Therapeutics1.9846 of 5 stars$4.93+6.0%$8.00+62.3%+4.5%$279.84MN/A-5.8040Gap UpAVIRAtea Pharmaceuticals2.637 of 5 stars$3.20-0.6%$6.88+115.0%-27.5%$273.68MN/A-1.5570ZYBTZhengye BiotechnologyN/A$5.80+18.9%N/AN/A$273.56M$189.75M0.00278News CoverageHigh Trading VolumeCRVSCorvus Pharmaceuticals2.3021 of 5 stars$4.25-1.4%$12.38+191.2%+89.9%$273.09MN/A-4.5730Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageMBXMBX Biosciences1.4972 of 5 stars$8.13+3.0%$37.25+358.2%N/A$271.74MN/A0.0036Gap DownIMMPImmutep1.8505 of 5 stars$1.84-2.1%$8.50+362.0%-20.2%$267.83M$5.14M0.002,021 Remove Ads Related Companies and Tools Related Companies Gossamer Bio Competitors COMPASS Pathways Competitors Septerna Competitors Candel Therapeutics Competitors Design Therapeutics Competitors Atea Pharmaceuticals Competitors Zhengye Biotechnology Competitors Corvus Pharmaceuticals Competitors MBX Biosciences Competitors Immutep Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVTE) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AVTE Stock Free AVTE Stock Alerts